FDA en­cour­ages col­lab­o­ra­tion be­tween mon­o­clon­al an­ti­body spon­sors to keep pace with emerg­ing Covid vari­ants

The FDA is en­cour­ag­ing de­vel­op­ers of Covid-19 mon­o­clon­al an­ti­bod­ies to col­lab­o­rate and bet­ter tar­get emerg­ing vari­ants in fi­nal guid­ance pub­lished on Wednes­day.

The reg­u­la­tor ex­plained the emer­gency use au­tho­riza­tion de­c­la­ra­tion of the Food, Drug and Cos­met­ic Act is still in place even though the pub­lic health emer­gency has end­ed. The FDA ex­pects the spon­sors that re­ceive EUAs should con­tin­ue to col­lect da­ta and work to­ward sub­mit­ting their prod­ucts for full ap­proval “as soon as pos­si­ble.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER